

Small Molecule Inhibitors of Mitochondrial Division: Tools that Translate Basic Biological Research into Medicine

Laura L. Lackner¹ and Jodi Nunnari^{1,*}

¹Department of Molecular and Cellular Biology, University of California, Davis, Davis, CA 95616, USA

*Correspondence: jnunnari@ucdavis.edu

DOI 10.1016/j.chembiol.2010.05.016

Mitochondria do not exist as discrete static entities; rather, mitochondria form a network that continuously moves, divides, and fuses. The structure of this dynamic network is in part maintained by a balance of division and fusion events (Hoppins et al., 2007). The ratio of division to fusion events that defines a proper balance is not universal but varies with developmental stage, cell type, and biological circumstances. This is evident throughout the cell cycle in higher eukaryotes, where mitochondria elongate during the G1/S transition and fragment at the onset of mitosis, and when mitochondria fragment in response to certain cellular stimuli, such as increases in cytosolic calcium levels (Breckenridge et al., 2003; Cereghetti et al., 2008; Han et al., 2008; Mitra et al., 2009; Taguchi et al., 2007). The functional state and distribution of mitochondria are clearly influenced by its steady-state structure. When the normal balance of division and fusion is disrupted as a consequence of the inappropriate stimulation or inhibition of either process, problems arise at the cellular level that compromises the well-being of the organism as a whole. This is evident by the ever-increasing number of diseases in which abnormal mitochondrial dynamics have been etiologically implicated. In this context, the mitochondrial division and fusion machines are valuable and interesting targets of small molecule effectors, as inhibition or activation of these processes may be able to restore the proper dynamic balance and function. A small molecule inhibitor of mitochondrial division, mdivi-1, has already been identified and characterized (Cassidy-Stone et al., 2008). This inhibitor has provided valuable insight into the mechanism of mitochondrial division and has shown great therapeutic promise in a wide array of disease models. This review will focus on small molecule effectors of mitochondrial division, discussing their value in basic biological research as well as their therapeutic potential.

Mitochondrial Dynamics in Healthy and Disease States: A Case for Identifying Small Molecule Inhibitors of Mitochondrial Division

Mitochondrial division and fusion are antagonistic activities whose fundamental roles are to create a compartment that is a connected conductor, able to mix its contents and have access to mtDNA and its products, but able to be distributed to distant cellular destinations via transport on actin or microtubule networks. In both yeast and higher eukaryotes, disruption of mitochondrial division leads to an extensively interconnected and collapsed mitochondrial network that leaves many areas of the cell devoid of the organelle. In contrast, defects in mitochondrial fusion cause extensive mitochondrial fragmentation and a complete or partial loss of mtDNA in yeast and mammalian cells, respectively (Hoppins et al., 2007). Disrupting division and fusion in yeast is not a lethal event. In contrast, the effects of disrupted division and fusion in higher eukaryotes are much more adverse to the organism. Mice lacking the dynamin related proteins (DRPs) that comprise the heart of mitochondrial division and fusion machines, Drp1 and MFN1/2 or OPA1, respectively, exhibit deleterious developmental defects (Chen et al., 2003; Davies et al., 2007; Ishihara et al., 2009; Wakabayashi et al., 2009). Mutations in human Drp1 cause early infant mortality, and mutations in MFN2 and OPA1 cause two distinct types of neurodegenerative diseases, Charcot Marie Tooth 2A (CMT2A) and dominant optic

atrophy (DOA), underscoring the essential nature of mitochondrial dynamics in higher eukaryotes (Alexander et al., 2000; Delettre et al., 2000; Waterham et al., 2007; Zuchner et al., 2006).

Improper mitochondrial distribution and morphology, as a result of attenuated division and fusion, are likely to be major causes of many adverse effects. However, the disruption of mitochondrial dynamics also has negative effects on mitochondrial function that are not as easily explained by changes in the overall steady-state structure or content mixing of the organelle. In cells that lack MFN2 or express CMT2A-associated disease alleles of MFN2, axonal transport of mitochondria is disrupted (Baloh et al., 2007); Interestingly, this disruption in transport does not appear to be a consequence of attenuated fusion, suggesting a fusion-independent role for MFN2 in the regulation of mitochondrial motility (Misko et al., 2010). In the absence of ongoing mitochondrial division, general mitochondrial dysfunction, such as loss of membrane potential, increase in ROS, increase in oxidized proteins, and loss of mitochondrial DNA, are observed (Lee et al., 2007; Parone et al., 2008; Twig et al., 2008; Yoon et al., 2006). These sublethal stresses induce senescence-associated phenotypic changes in cells, highlighting the intimate connection between mitochondrial function and cellular function (Lee et al., 2007; Yoon et al., 2006).

Mitochondrial dynamics have also been proposed to play a role in the quality control of the organelle. Studies have shown that




Figure 1. Modulation of Drp1-Mediated Mitochondrial Division and Potentiation of Apoptosis by Negative and Positive Effectors
Negative effectors may block Drp1 assembly, as is the case for mdivi-1, or other critical aspects of Drp1 function and thus attenuate mitochondrial division and/or mitochondrial outer membrane permeabilization (MOMP). Positive effectors may stimulate Drp1 assembly and/or function and, depending on the distinct set of effectors, which are likely defined by biological circumstances, mitochondrial division and/or MOMP can be stimulated.

during a division event, functionally asymmetric daughter mitochondria with different membrane potentials can be produced. The functional daughter, which retains a high membrane potential, can re-fuse with the mitochondrial network, while the dysfunctional daughter cannot re-fuse due to low membrane potential and is subsequently flagged for autophagic degradation (Parone et al., 2008; Twig et al., 2008). This is consistent with recent work on the Pink1/Parkin pathway, which demonstrates that the selective Pink1-dependent recruitment of Parkin, an E3-ubiquitin ligase, to mitochondria with low-membrane potential targets the damaged organelles for degradation (Matsuda et al., 2010; Narendra et al., 2008; Narendra et al., 2010). Thus, it is possible that the increase in dysfunctional mitochondria in the absence of division may be due to the loss of a role for division in the quality control of the mitochondrial compartment.

Current data suggest that Drp1 also plays an independent role in the regulation of intrinsic apoptosis, specifically via the control of outer membrane permeabilization by the pro-apoptotic Bcl2 protein, Bax (Figure 1). Concomitant with mitochondrial outer membrane permeabilization during apoptosis, Drp1 self-assembly and its recruitment to mitochondria are increased, resulting in an enhanced rate of Drp1-dependent mitochondrial division and mitochondrial fragmentation (Breckenridge et al., 2003; Frank et al., 2001; Wasiak et al., 2007). Inhibition of Drp1-dependent mitochondrial division delays and partially inhibits apoptosis, suggesting a functional link between the progression of apoptosis and Drp1-mediated mitochondrial fragmentation. Mitochondrial fusion also plays a role in the regulation of apoptosis (Frank et al., 2001; Jagasia et al., 2005; Lee et al., 2004). In contrast to Drp1, MFN1 and MFN2 are thought

to play a protective role against apoptosis in cells as the inhibition of fusion makes cells more sensitive to apoptotic stimuli.

Given the importance of mitochondrial dynamics for cellular function, regulation, and cell death, it is perhaps not surprising that aberrant mitochondrial dynamics/morphology have been associated with numerous and prevalent human diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and diabetes (Poole et al., 2008; Wang et al., 2009; Zorzano et al., 2009). In these cases, fragmentation of the mitochondrial network has been observed in disease patient samples and/or in cell culture disease models, suggesting a shift in the division/fusion balance toward division. The cause of the shift in each case is unclear and could be a result of direct activation of mitochondrial division, direct inhibition of mitochondrial fusion, or both, or as an indirect result of cellular stress, which can affect the division/fusion balance. In the cases of the mitochondrial fusion-linked diseases DOA and CMT2A, it is clear that the disease-associated mitochondrial morphologies are at least in part due to a direct shift toward division as a result of attenuated fusion. The link between increased mitochondrial division and disease states, and between mitochondrial division and apoptosis makes the mitochondrial division machine an attractive target for therapeutics that could treat an impressive array of diseases from neurodegeneration to more acute conditions, such as stroke, myocardial infarction, and drug toxicity.

The Mitochondrial Division Machine: A Deep Target for Small Molecule Effectors

The heart of the mitochondrial division machine is the dynamin-related GTPase Dnm1 (yeast)/Drp1 (mammals). While cytological analysis, which places Dnm1/Drp1 at sites of mitochondrial division, provides compelling support for the role of Dnm1/Drp1 as the master regulator of mitochondrial division, biochemical and structural analyses of the yeast mitochondrial division dynamin have provided the insight needed for a mechanistic understanding of how Dnm1/Drp1 does the work of mitochondrial division (Ingerman et al., 2005; Legesse-Miller et al., 2003; Naylor et al., 2006; Sesaki and Jensen, 1999). These analyses have suggested a model in which GTP binding to Dnm1 dimers produces conformational changes that facilitate the assembly of Dnm1 into helical structures (Ingerman et al., 2005). These helical structures possess diameters that match the diameters of mitochondrial constriction sites *in vivo*, indicating that Dnm1 self-assembly drives mitochondrial constriction (Figure 1). Dnm1 self-assembly also stimulates GTP hydrolysis, which is required for mitochondrial division, likely by producing additional structural changes in the Dnm1 helix and by promoting disassembly (Ingerman et al., 2005; Naylor et al., 2006). Interestingly, Dnm1 self-assembly proceeds via a rate-limiting, Dnm1 concentration-dependent nucleation event, which may be exploited as a means to regulate the assembly and thus the function of Dnm1 *in vivo* (Ingerman et al., 2005).

The mammalian mitochondrial division dynamin Drp1 also assembles into helical structures that can tubulate liposomes *in vitro*, albeit with smaller diameters than those formed by Dnm1, and thus likely functions via a similar mechanism (Smirnova et al., 2001; Yoon et al., 2001). While the basic mechanism of membrane division is likely conserved, regulation of

Drp1 assembly is more complex and regulated likely because Drp1 self-assembly and/or assembly associated conformational changes have been harnessed in mammalian cells to integrate mitochondrial division with cellular physiology. This is evident when comparing the steady-state cellular distributions of the two proteins. In contrast to Dnm1, which predominantly exists in assembled structures, Drp1 is mainly distributed in a diffuse manner throughout the cytosol in cultured cells, which suggests that it is predominantly unassembled (Labrousse et al., 1999; Otsuga et al., 1998; Sesaki and Jensen, 1999; Smirnova et al., 2001). However, in response to certain cellular stimuli such as increases in cytosolic calcium levels or the initiation of apoptosis, mitochondrial targeting and assembly of Drp1 is greatly enhanced and consequently mitochondrial division is increased (Breckenridge et al., 2003; Frank et al., 2001; Germain et al., 2005). While the mechanisms underlying the regulation of Drp1 assembly are unclear, it is still evident that the regulation of assembly can be used as a means to regulate function.

Although DRPs are the heart of the division machine, mitochondrial division is strictly dependent on additional non-DRP factors. The roles of these factors are best characterized in yeast, where it is clear that two additional proteins, Fis1 and Mdv1, are essential for Dnm1-mediated mitochondrial division (Cerveny et al., 2001; Fekkes et al., 2000; Mozdy et al., 2000; Tieu and Nunnari, 2000). Fis1 is anchored to the mitochondrial outer membrane via a C-terminal transmembrane domain. The N terminus of the protein is exposed to the cytosol and interacts directly with Mdv1 (Dohm et al., 2004; Karren et al., 2005; Mozdy et al., 2000; Suzuki et al., 2003, 2005; Tieu and Nunnari, 2000; Tieu et al., 2002). Mdv1 functions as a molecular bridge between mitochondrial-anchored Fis1 and soluble Dnm1, and together Fis1 and Mdv1 function to target Dnm1 to the mitochondrial surface (Griffin et al., 2005; Karren et al., 2005; Tieu and Nunnari, 2000; Tieu et al., 2002). Recent work has demonstrated that Mdv1 also functions posttargeting to nucleate the assembly of Dnm1 on the mitochondrial surface. Indeed, biochemical and cytological evidence suggests that the native yeast division machine is a structure comprised of coassembled Dnm1 and Mdv1 (Lackner et al., 2009). Two additional Dnm1-interacting proteins, Caf4, which is an Mdv1 paralog, and Num1, which is a coiled-coil protein localized to the cell cortex, have been identified but are not essential for division (Cerveny et al., 2007; Griffin et al., 2005). How these proteins act together combinatorially with Fis1 and Mdv1 to modulate division and potentially other processes in the cell will provide additional insight into the regulation and functions of the division DRP.

In mammalian cells, several non-DRP proteins have been identified as important regulators of mitochondrial division; however, their precise functions have not yet been determined. For example, a mammalian Fis1 ortholog has been identified and likely plays a role in division, but it is not essential for Drp1 targeting, suggesting that additional pathways for Drp1 activation have evolved in mammalian cells (Lee et al., 2004; Stojanovski et al., 2004; Suzuki et al., 2003). Indeed, a structural or functional ortholog of Mdv1 has not yet been identified in higher eukaryotes. Given that division is more integrated and regulated in mammalian cells, it seems likely that Mdv1 has been replaced by several adaptor and/or nucleator type components that perform similar essential functions in division, but may be present

in a cell type-specific manner and/or respond to different cellular signaling pathways (Lackner and Nunnari, 2008). Candidates for Drp1 effectors in mammalian cells include the mitochondrial outer membrane proteins, hFis1, Mff, and GDAP1 (ganglioside-induced differentiation associated protein 1), which when mutated causes CMT, the inner membrane space protein MTP18 and the BAR domain protein, Endophilin B1 (Gandre-Babbe and van der Bliek, 2008; Karbowski et al., 2004; Lee et al., 2004; Niemann et al., 2005; Stojanovski et al., 2004; Suzuki et al., 2003; Tondera et al., 2005, 2004). Also, during apoptosis, both Bax and Drp1 translocate to the mitochondrial outer membrane and colocalize in foci on mitochondria, suggesting that Bax and potentially other Bcl2 family member proteins also function as effectors of Drp1 activity, as suggested by the finding that Bcl-x_L overexpression positively regulates Drp1 to stimulate synapse formation (Karbowski et al., 2002; Li et al., 2008). In addition to these potential protein regulators of mitochondrial division, the function of Drp1 is also influenced by posttranslational modification. Phosphorylation, nitrosylation, ubiquitination, and sumoylation have all been identified as post-translational modifications that can positively or negatively affect the function of Drp1 (Cereghetti et al., 2008; Chang and Blackstone, 2007; Cho et al., 2009; Cribbs and Strack, 2007; Han et al., 2008; Harder et al., 2004; Nakamura et al., 2006; Taguchi et al., 2007; Yonashiro et al., 2006; Zunino et al., 2007). It is likely that a distinct combination of protein effectors and posttranslational modifications regulate the activity of Drp1 in different physiological contexts (Figure 1).

While the mitochondrial division machine is comprised of and influenced by many factors, the mitochondrial division dynamins Dnm1 and Drp1 are the most obvious targets of small molecule modulators of division. They are the highly conserved, core mechanical component of the division machine and are the best understood mechanistically. In addition, the division DRP is a deep target for small molecule effectors, since there are many functionally critical features of the protein, such as GTP binding, GTP hydrolysis, and self-assembly, which is mediated by conformational changes linked to the GTPase cycle. Therefore, small molecule effectors that target different functional facets of Dnm1/Drp1 and thus either positively or negatively affect distinct stages of Dnm1/Drp1-driven mitochondrial division can be identified. Finally, given the increasing number of Drp1-interacting proteins that have been implicated in division, it may be possible to identify tissue-specific or context-specific inhibitors of mitochondrial division by identifying small molecules that target and modulate Drp1-effector interactions.

Mdivi-1: The First Inhibitor of the Mitochondrial Division DRP

Using a simple growth-based assay in yeast, the first small molecule effector of the mitochondrial division DRP, Dnm1, was identified and was demonstrated to also target Drp1 in mammalian cells (Cassidy-Stone et al., 2008), speaking to the conserved primary mechanism of mitochondrial division. Mechanistically, mdivi-1 acts as a mixed type inhibitor to attenuate the early stages of division DRP assembly by preventing the polymerization of higher order structures. Mdivi-1 selectively targets the unassembled pool of the mitochondrial division dynamin, and its binding creates and/or stabilizes an assembly-deficient

Table 1. The Therapeutic Potential of Genetic and Chemical Inhibition of Mitochondrial Division

| Disease/Injury | Effects of inhibited mitochondrial division | Method of inhibition | References |
|-------------------------------------|--|----------------------|--|
| Parkinson's disease | Attenuation of the adverse effects Pink1 and Parkin mutants have on mitochondrial function and morphology in PD disease models | Genetic and chemical | Lutz et al., 2009 Cui et al., 2010 |
| Alzheimer's disease | Attenuation of β -amyloid protein- or nitric oxide-induced mitochondrial fragmentation and neuronal cell damage | Genetic | Barsoum et al., 2006 Cho et al., 2009 |
| Huntington's disease | Attenuation of the adverse effects of Htt mutations on mitochondrial function and morphology | Genetic | Wang et al., 2009 |
| Ischemia/reperfusion injury | Protection against cardiac injury in a murine model of ischemia/reperfusion | Genetic and chemical | Ong et al., 2010 |
| | Protection against renal injury in a rodent model of ischemia/reperfusion | Genetic and chemical | Brooks et al., 2009 |
| Drug toxicity-induced tissue damage | Protection against cisplatin-induced renal damage | Genetic and chemical | Brooks et al., 2009 |

conformation (Figure 1). Assembly of the division DRP is critical for function; thus, mdivi-1 acts as an efficacious inhibitor of mitochondrial division in cells. Given the conservation of the DRP super family members, it is remarkable that mdivi-1 also displays a high degree of selectivity for the mitochondrial division dynamins. It has no effect on other DRPs, such as the endocytic dynamin or the mitochondrial fusion dynamins. This selectivity is encouraging for the division dynamin as a therapeutic target (see below). Systems are in place to screen for additional small molecule effectors of the mitochondrial division dynamin, as both cellular and biochemical assays of Dnm1/Drp1 activity and function are well established. In addition, these assays can be used, as they were for mdivi-1, to precisely identify the cellular and biochemical activities of the division DRP.

The identification of mdivi-1 and other likely inhibitors of the mitochondrial division dynamin have and will continue to prove beneficial in dissecting the exact roles mitochondrial division, or Drp1 specifically, plays in the maintenance of proper cellular function. These small molecule effectors can extend the resolution of genetic, cytological, and biochemical approaches by allowing discrete steps in mitochondrial division or Drp1 activities to be modulated selectively, rapidly, and reversibly. This modulation can occur in an otherwise wild-type background without the need for the generation of mutant or knockout cell lines or the depletion of protein levels by techniques such as RNAi. Thus, complications from second site suppressors or indirect effects can be reduced. In addition, the effects of increased or decreased Drp1 activity can be monitored immediately. Thus, the evolution of the cellular defects associated with loss of Drp1 activity can be tracked over time, providing a clearer picture of the primary and secondary consequences of aberrant Drp1 function. Also, when used in combination with biochemical assays, biochemical activity can be correlated with cellular function. Indeed, mdivi-1 has already proven to be useful as a tool to identify the role of Drp1 in intrinsic apoptosis. Specifically, in cell-free MOMP assays where mitochondrial division does not occur, mdivi-1 blocks cytochrome-c release (Cassidy-Stone et al., 2008). Thus, Drp1 has a positive regulatory role in MOMP that is independent of its role in mitochondrial division, demonstrating that Drp1 possesses multiple independent roles in mammalian cells (Figure 1). In addition, the use of mdivi-1

for the acute inhibition of Drp1 activity in cultured mammalian cells has revealed a regulatory role for a hyperfused mitochondrial state in the regulation of cyclin E levels and consequently in cell cycle progression (Mitra et al., 2009).

The Therapeutic Potential of Small Molecule Effectors of Mitochondrial Division: Putting mdivi-1 to the Test

While the etiology of many diseases in which aberrant mitochondrial morphology is observed is uncertain, inhibiting mitochondrial division with mdivi-1 in Parkinson's disease cell culture models or a dominant negative form of Drp1 in Alzheimer's and Huntington's disease cell culture models attenuates disease-associated phenotypes (Barsoum et al., 2006; Cho et al., 2009; Cui et al., 2010; Lutz et al., 2009; Wang et al., 2009) (Table 1). These results demonstrate the therapeutic potential of small molecule inhibitors of mitochondrial division to disease. The role of Drp1 in the facilitation of apoptosis has also been exploited for its therapeutic potential (Table 1). The reperfusion of ischemic cells as a result of events such as stroke or myocardial infarction induces apoptotic cell death, which can lead to severe tissue and organ damage. In these cases, small molecule inhibitors of Drp1 may serve to protect against apoptotic cell death following such a temporary insult. Indeed, this approach seems promising, as the therapeutic potential of Drp1 inhibition using genetic approaches and also with mdivi-1 has now been tested with good success in experimental models of cardiac and renal ischemia/reperfusion (Brooks et al., 2009; Ong et al., 2010). In addition, it has been shown that mdivi-1 is efficacious in rodent models of cisplatin-induced renal damage, also a result of apoptotic cell death (Brooks et al., 2009). Thus inhibitors of Drp1 have potential therapeutic application for a wider array of drug toxicity-induced tissue damage.

Although not yet put to the test, it seems likely that mdivi-1 or other inhibitors of mitochondrial division will prove beneficial to the mitochondrial fusion-linked neuropathies CMT2A and DOA, where the detrimental effects of ongoing division in the absence or attenuation of mitochondrial fusion are clearly evident (Alexander et al., 2000; Delettre et al., 2000; Kijima et al., 2005). Interestingly, recent work has shown that partial restoration of mitochondrial fusion in mammalian cells can rescue the longer term defects associated with loss of fusion: decreased

respiratory capacity, reduction in mtDNA levels, and increased rates of mtDNA mutation (Chen et al., 2005, 2010). Thus, small molecule inhibitors of mitochondrial division, which can serve to restore the connectivity of the mitochondrial network, may also rescue the defects associated with loss/attenuation of fusion. Inhibitors of Drp1 are also logical potential therapeutics in cases of human diseases caused by heteroplasmic mtDNA mutations. Inhibition of mitochondrial division would increase connectivity of mitochondria and enhance access to wild-type products of mtDNA genes to allow for complementation of respiratory or other dysfunction. It is important to note, however, that mitochondrial division is an essential event in cells (Ishihara et al., 2009; Wakabayashi et al., 2009; Waterham et al., 2007). Indeed, stimulation of mitochondrial division enhances mitochondrial mass and distribution in neurons and stimulates synapse formation (Li et al., 2008). Mitochondrial division may also be an essential event for mitochondrial quality control. In this context, the mechanism of mdivi-1 inhibition is advantageous as it can act much like a dimmer switch on a light bulb, to cause increasing degrees of mitochondrial connectivity, which provide for efficacy while allowing for distribution and other Drp1 related functions. Finally, although not yet discovered, small molecule activators of Drp1 and inhibitors of mitochondrial fusion DRPs are attractive as anti-cancer therapies as they have potential to stimulate apoptotic cell death.

ACKNOWLEDGMENTS

This work was supported by an NIH grant to J.N. (GM062942).

REFERENCES

- Alexander, C., Votruba, M., Pesch, U.E.A., Thiselton, D.L., Mayer, S., Moore, A., Rodriguez, M., Kellner, U., Leo-Kottler, B., Auburger, G., et al. (2000). *Nat. Genet.* 26, 211–215.
- Baloh, R.H., Schmidt, R.E., Pestronk, A., and Milbrandt, J. (2007). *J. Neurosci.* 27, 422–430.
- Barsoum, M.J., Yuan, H., Gerencser, A.A., Liot, G., Kushnareva, Y., Graber, S., Kovacs, I., Lee, W.D., Waggoner, J., Cui, J., et al. (2006). *EMBO J.* 25, 3900–3911.
- Breckenridge, D.G., Stojanovic, M., Marcellus, R.C., and Shore, G.C. (2003). *J. Cell Biol.* 160, 1115–1127.
- Brooks, C., Wei, Q., Cho, S.G., and Dong, Z. (2009). *J. Clin. Invest.* 119, 1275–1285.
- Cassidy-Stone, A., Chipuk, J.E., Ingeman, E., Song, C., Yoo, C., Kuwana, T., Kurth, M.J., Shaw, J.T., Hinshaw, J.E., Green, D.R., et al. (2008). *Dev. Cell* 14, 193–204.
- Cereghetti, G.M., Stangherlin, A., Martins de Brito, O., Chang, C.R., Blackstone, C., Bernardi, P., and Scorrano, L. (2008). *Proc. Natl. Acad. Sci. USA* 105, 15803–15808.
- Cervený, K.L., McCaffery, J.M., and Jensen, R.E. (2001). *Mol. Biol. Cell* 12, 309–321.
- Cervený, K.L., Studer, S.L., Jensen, R.E., and Sesaki, H. (2007). *Dev. Cell* 12, 363–375.
- Chang, C.R., and Blackstone, C. (2007). *J. Biol. Chem.* 282, 21583–21587.
- Chen, H., Detmer, S.A., Ewald, A.J., Griffin, E.E., Fraser, S.E., and Chan, D.C. (2003). *J. Cell Biol.* 160, 189–200.
- Chen, H., Chomyn, A., and Chan, D.C. (2005). *J. Biol. Chem.* 280, 26185–26192.
- Chen, H., Vermulst, M., Wang, Y.E., Chomyn, A., Prolla, T.A., McCaffery, J.M., and Chan, D.C. (2010). *Cell* 141, 280–289.
- Cho, D.H., Nakamura, T., Fang, J., Cieplak, P., Godzik, A., Gu, Z., and Lipton, S.A. (2009). *Science* 324, 102–105.
- Cribbs, J.T., and Strack, S. (2007). *EMBO Rep.* 8, 939–944.
- Cui, M., Tang, X., Christian, W.V., Yoon, Y., and Tieu, K. (2010). *J. Biol. Chem.* 285, 11740–11752.
- Davies, V.J., Hollins, A.J., Piechota, M.J., Yip, W., Davies, J.R., White, K.E., Nicols, P.P., Boulton, M.E., and Votruba, M. (2007). *Hum. Mol. Genet.* 16, 1307–1318.
- Delettre, C., Lenaers, G., Griffoin, J.-M., Gigarel, N., Lorenzo, C., Belenguer, P., Pelloquin, L., Grosgeorge, J., Turc-Carel, C., Perret, E., et al. (2000). *Nat. Genet.* 26, 207–210.
- Dohm, J.A., Lee, S.J., Hardwick, J.M., Hill, R.B., and Gittis, A.G. (2004). *Proteins* 54, 153–156.
- Fekkes, P., Shepard, K.A., and Yaffe, M.P. (2000). *J. Cell Biol.* 151, 333–340.
- Frank, S., Gaume, B., Bergmann-Leitner, E.S., Leitner, W., Robert, E.G., Catez, F., Smith, C.L., and Youle, R.J. (2001). *Dev. Cell* 1, 515–525.
- Gandre-Babbe, S., and van der Bliek, A.M. (2008). *Mol. Biol. Cell* 19, 2402–2412.
- Germain, M., Mathai, J.P., McBride, H.M., and Shore, G.C. (2005). *EMBO J.* 24, 1546–1556.
- Griffin, E.E., Graumann, J., and Chan, D.C. (2005). *J. Cell Biol.* 170, 237–248.
- Han, X.J., Lu, Y.F., Li, S.A., Kaitsuka, T., Sato, Y., Tomizawa, K., Nairn, A.C., Takei, K., Matsui, H., and Matsushita, M. (2008). *J. Cell Biol.* 182, 573–585.
- Harder, Z., Zunino, R., and McBride, H. (2004). *Curr. Biol.* 14, 340–345.
- Hoppins, S., Lackner, L., and Nunnari, J. (2007). *Annu. Rev. Biochem.* 76, 751–780.
- Ingeman, E., Perkins, E.M., Marino, M., Mears, J.A., McCaffery, J.M., Hinshaw, J.E., and Nunnari, J. (2005). *J. Cell Biol.* 170, 1021–1027.
- Ishihara, N., Nomura, M., Jofuku, A., Kato, H., Suzuki, S.O., Masuda, K., Otera, H., Nakanishi, Y., Nonaka, I., Goto, Y., et al. (2009). *Nat. Cell Biol.* 11, 958–966.
- Jagasia, R., Grote, P., Westermann, B., and Conradt, B. (2005). *Nature* 433, 754–760.
- Karbowskii, M., Lee, Y.J., Gaume, B., Jeong, S.Y., Frank, S., Nechushtan, A., Santel, A., Fuller, M., Smith, C.L., and Youle, R.J. (2002). *J. Cell Biol.* 159, 931–938.
- Karbowskii, M., Jeong, S.Y., and Youle, R.J. (2004). *J. Cell Biol.* 166, 1027–1039.
- Karren, M.A., Coonrod, E.M., Anderson, T.K., and Shaw, J.M. (2005). *J. Cell Biol.* 171, 291–301.
- Kijima, K., Numakura, C., Izumino, H., Umetsu, K., Nezu, A., Shiiki, T., Ogawa, M., Ishizaki, Y., Kitamura, T., Shozawa, Y., et al. (2005). *Hum. Genet.* 116, 23–27.
- Labrousse, A.M., Zappaterra, M.D., Rube, D.A., and van der Bliek, A.M. (1999). *Mol. Cell* 4, 815–826.
- Lackner, L.L., and Nunnari, J.M. (2008). *Biochim. Biophys. Acta* 1792, 1138–1144.
- Lackner, L.L., Horner, J.S., and Nunnari, J. (2009). *Science* 325, 874–877.
- Lee, Y.J., Jeong, S.Y., Karbowskii, M., Smith, C.L., and Youle, R.J. (2004). *Mol. Biol. Cell* 15, 5001–5011.
- Lee, S., Jeong, S.Y., Lim, W.C., Kim, S., Park, Y.Y., Sun, X., Youle, R.J., and Cho, H. (2007). *J. Biol. Chem.* 282, 22977–22983.
- Legesse-Miller, A., Massol, R.H., and Kirchhausen, T. (2003). *Mol. Biol. Cell* 14, 1953–1963.

- Li, H., Chen, Y., Jones, A.F., Sanger, R.H., Collis, L.P., Flannery, R., McNay, E.C., Yu, T., Schwarzenbacher, R., Bossy, B., et al. (2008). *Proc. Natl. Acad. Sci. USA* **105**, 2169–2174.
- Lutz, A.K., Exner, N., Fett, M.E., Schlehe, J.S., Kloos, K., Lammermann, K., Brunner, B., Kurz-Drexler, A., Vogel, F., Reichert, A.S., et al. (2009). *J. Biol. Chem.* **284**, 22938–22951.
- Matsuda, N., Sato, S., Shiba, K., Okatsu, K., Saisho, K., Gautier, C.A., Sou, Y.S., Saiki, S., Kawajiri, S., Sato, F., et al. (2010). *J. Cell Biol.* **189**, 211–221.
- Misko, A., Jiang, S., Wegorzewska, I., Milbrandt, J., and Baloh, R.H. (2010). *J. Neurosci.* **30**, 4232–4240.
- Mitra, K., Wunder, C., Roysam, B., Lin, G., and Lippincott-Schwartz, J. (2009). *Proc. Natl. Acad. Sci. USA* **106**, 11960–11965.
- Mozdy, A.D., McCaffery, J.M., and Shaw, J.M. (2000). *J. Cell Biol.* **151**, 367–379.
- Nakamura, N., Kimura, Y., Tokuda, M., Honda, S., and Hirose, S. (2006). *EMBO Rep.* **7**, 1019–1022.
- Narendra, D., Tanaka, A., Suen, D.F., and Youle, R.J. (2008). *J. Cell Biol.* **183**, 795–803.
- Narendra, D.P., Jin, S.M., Tanaka, A., Suen, D.F., Gautier, C.A., Shen, J., Cookson, M.R., and Youle, R.J. (2010). *PLoS Biol.* **8**, e1000298.
- Naylor, K., Ingeman, E., Okreglak, V., Marino, M., Hinshaw, J.E., and Nunnari, J. (2006). *J. Biol. Chem.* **281**, 2177–2183.
- Niemann, A., Ruegg, M., La Padula, V., Schenone, A., and Suter, U. (2005). *J. Cell Biol.* **170**, 1067–1078.
- Ong, S.B., Subrayan, S., Lim, S.Y., Yellon, D.M., Davidson, S.M., and Hausenloy, D.J. (2010). *Circulation* **121**, 2012–2022.
- Otsuga, D., Keegan, B.R., Brisch, E., Thantcher, J.W., Hermann, G.J., Bleazard, W., and Shaw, J. (1998). *J. Cell Biol.* **143**, 333–349.
- Parone, P.A., Da Cruz, S., Tondera, D., Mattenberger, Y., James, D.I., Maechler, P., Barja, F., and Martinou, J.C. (2008). *PLoS ONE* **3**, e3257.
- Poole, A.C., Thomas, R.E., Andrews, L.A., McBride, H.M., Whitworth, A.J., and Pallanck, L.J. (2008). *Proc. Natl. Acad. Sci. USA* **105**, 1638–1643.
- Sesaki, H., and Jensen, R.E. (1999). *J. Cell Biol.* **147**, 699–706.
- Smirnova, E., Griparic, L., Shurland, D.L., and van Der Bliek, A.M. (2001). *Mol. Biol. Cell* **12**, 2245–2256.
- Stojanovski, D., Koutsopoulos, O.S., Okamoto, K., and Ryan, M.T. (2004). *J. Cell Sci.* **117**, 1201–1210.
- Suzuki, M., Jeong, S.Y., Karbowski, M., Youle, R.J., and Tjandra, N. (2003). *J. Mol. Biol.* **334**, 445–458.
- Suzuki, M., Neutzner, A., Tjandra, N., and Youle, R.J. (2005). *J. Biol. Chem.* **280**, 21444–21452.
- Taguchi, N., Ishihara, N., Jofuku, A., Oka, T., and Mihara, K. (2007). *J. Biol. Chem.* **282**, 11521–11529.
- Tieu, Q., and Nunnari, J. (2000). *J. Cell Biol.* **151**, 353–365.
- Tieu, Q., Okreglak, V., Naylor, K., and Nunnari, J. (2002). *J. Cell Biol.* **158**, 445–452.
- Tondera, D., Santel, A., Schwarzer, R., Dames, S., Giese, K., Klippel, A., and Kaufmann, J. (2004). *J. Biol. Chem.* **279**, 31544–31555.
- Tondera, D., Czauderna, F., Paulick, K., Schwarzer, R., Kaufmann, J., and Santel, A. (2005). *J. Cell Sci.* **118**, 3049–3059.
- Twig, G., Elorza, A., Molina, A.J., Mohamed, H., Wikstrom, J.D., Walzer, G., Stiles, L., Haigh, S.E., Katz, S., Las, G., et al. (2008). *EMBO J.* **27**, 433–446.
- Wakabayashi, J., Zhang, Z., Wakabayashi, N., Tamura, Y., Fukaya, M., Kensler, T.W., Iijima, M., and Sesaki, H. (2009). *J. Cell Biol.* **186**, 805–816.
- Wang, X., Su, B., Lee, H.G., Li, X., Perry, G., Smith, M.A., and Zhu, X. (2009). *J. Neurosci.* **29**, 9090–9103.
- Wasiak, S., Zunino, R., and McBride, H.M. (2007). *J. Cell Biol.* **177**, 439–450.
- Waterham, H.R., Koster, J., van Roermund, C.W., Mooyer, P.A., Wanders, R.J., and Leonard, J.V. (2007). *N. Engl. J. Med.* **356**, 1736–1741.
- Yonashiro, R., Ishido, S., Kyo, S., Fukuda, T., Goto, E., Matsuki, Y., Ohmura-Hoshino, M., Sada, K., Hotta, H., Yamamura, H., et al. (2006). *EMBO J.* **25**, 3618–3626.
- Yoon, Y., Pitts, K.R., and McNiven, M.A. (2001). *Mol. Biol. Cell* **12**, 2894–2905.
- Yoon, Y.S., Yoon, D.S., Lim, I.K., Yoon, S.H., Chung, H.Y., Rojo, M., Malka, F., Jou, M.J., Martinou, J.C., and Yoon, G. (2006). *J. Cell. Physiol.* **209**, 468–480.
- Zorzano, A., Liesa, M., and Palacin, M. (2009). *Int. J. Biochem. Cell Biol.* **41**, 1846–1854.
- Zuchner, S., De Jonghe, P., Jordanova, A., Claeys, K.G., Guergueltcheva, V., Cherninkova, S., Hamilton, S.R., Van Stavern, G., Krajewski, K.M., Stajich, J., et al. (2006). *Ann. Neurol.* **59**, 276–281.
- Zunino, R., Schauss, A., Rippstein, P., Andrade-Navarro, M., and McBride, H.M. (2007). *J. Cell Sci.* **120**, 1178–1188.